US · Healthcare · Biotechnology
EPS came in at -0.63 against a street estimate of -0.64 — a beat of 1.6%.
Analysts rate Artiva Biotherapeutics, Inc. Common Stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $35.80.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 36.73% |
| Viking Global Investors LP | 5.33% |
| Blackstone Inc | 4.92% |
| 5AM Venture Management, LLC | 4.81% |
| VR Adviser, LLC | 4.18% |
| Franklin Templeton Inc | 4.09% |
| Caligan Partners LP | 3.55% |
| Vanguard Capital Management, LLC | 2.01% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Artiva Biotherapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.